(S)-8-(2-methylpiperazin-1-yl)-5-phenylpyrido[3,2-d]pyridazine | 1133750-19-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (S)-8-(2-methylpiperazin-1-yl)-5-phenylpyrido[3,2-d]pyridazine
• 英文别名: (R)-8-(2-methylpiperazin-1-yl)-5-phenylpyrido[3,2-d]pyridazine；8-[(2R)-2-methylpiperazin-1-yl]-5-phenylpyrido[2,3-d]pyridazine
• CAS: 1133750-19-2
• 化学式: C₁₈H₁₉N₅
• 分子量: 305.382
• InChiKey: GRRDABQOBZTSDO-CYBMUJFWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.28
• 拓扑面积：
  53.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (S)-8-(2-methylpiperazin-1-yl)-5-phenylpyrido[3,2-d]pyridazine 、 苯甲酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以84%的产率得到8-((2R)-2-methyl-4-(phenylcarbonyl)-1-piperazinyl)-5-phenylpyrido[2,3-d]pyridazine
  参考文献：
  名称：

  Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines

  摘要：

  Pyridopyridazine antagonists of the hedgehog signaling pathway are described. Designed to optimize our previously described phthalazine smoothened antagonists, a representative compound eliminates a PXR liability while retaining potency and in vitro metabolic stability. Moreover, the compound has improved efficacy in a hedgehog/smoothened signaling mouse pharmacodynamic model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.006
• 作为产物：
  描述：

  (R)-tert-butyl 3-methyl-4-(5-phenylpyrido[3,2-d]pyridazin-8-yl)piperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以77%的产率得到(S)-8-(2-methylpiperazin-1-yl)-5-phenylpyrido[3,2-d]pyridazine
  参考文献：
  名称：

  Addressing PXR liabilities of phthalazine-based hedgehog/smoothened antagonists using novel pyridopyridazines

  摘要：

  Pyridopyridazine antagonists of the hedgehog signaling pathway are described. Designed to optimize our previously described phthalazine smoothened antagonists, a representative compound eliminates a PXR liability while retaining potency and in vitro metabolic stability. Moreover, the compound has improved efficacy in a hedgehog/smoothened signaling mouse pharmacodynamic model. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.06.006

文献信息

• Pyridopyridazine compounds, compositions and methods of use
  申请人：Kaizerman Jacob

  公开号：US20090099173A1

  公开（公告）日：2009-04-16

  The present invention relates generally to compounds represented in Formula I, pharmaceutical compositions comprising them and methods of treating of diseases or disorders such as cancer.

  本发明涉及一般表示为公式I的化合物，包括它们的制药组合物和治疗癌症等疾病或疾病的方法。
• ANNELATED PYRIDAZINES FOR THE TREATMENT OF TUMORS DRIVEN BY INAPPROPRIATE HEDGEHOG SIGNALLING
  申请人：Amgen Inc.

  公开号：EP2188283B1

  公开（公告）日：2012-08-15
• US8222251B2
  申请人：——

  公开号：US8222251B2

  公开（公告）日：2012-07-17